Metastatic MelanomaPhase 1/2NCT01340729
Open-Label Study of TPI 287 for Patients With Metastatic Melanoma
A Phase 1/2 study testing TPI 287 in people with Metastatic Melanoma, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
The goal of this clinical research study is to find the highest tolerable dose of TPI 287 that can be given to patients with metastatic melanoma. Researchers want to find out if TPI 287 can control the disease. The safety of TPI 287 will also be studied. Read more about this study
- Who is it for?
- Ages 15 years and older
- Conditions the study is for
- Metastatic Melanoma
- What is being tested?
- TPI 287
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- Sep 2013to Sep 2016
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Patients with histologically proven melanoma with metastasis that is unresectable Stage III or Stage IV. This will include bulky stage III and M1-3.
- Patients must have shown unequivocal evidence for tumor recurrence or progression and should have at least one indicator lesion that can be measured in one dimension as >/= 20mm with conventional techniques (CT, MRI, and X-ray) or >/= 10mm with spiral CT scan.
- Patients with melanoma with documented metastases to the brain are eligible: a. Must be asymptomatic with stable disease for at least 2 months as determined by CT or MRI of the brain at the time of evaluation no measurable changes. b. May have had prior therapy for brain metastasis such as whole brain irradiation, stereotactic gamma ray therapy or resection of brain metastases.
- Patients may have had up to two prior cytotoxic chemotherapy regimens for their systemic disease (immunological or targeted therapy e.g. vaccine, IL-2, B-RAF inhibitors, will not be considered prior cytotoxic chemotherapy)
- All patients must sign an informed consent indicating that they are aware of the investigational nature of this study in keeping with the policies of this hospital.
- Patients must have a Eastern Cooperative Oncology Group (ECOG) status of </= 2.
Show all 11Show fewer
- Patients must have recovered from the toxic effects of prior therapy (baseline grade), at least 3 weeks after the last dose was administered. Any questions about whether patients fulfill this criteria should be directed to the Study Chair.
- Patients must have adequate bone marrow function (Absolute neutrophil count (ANC)>/= 1,500/mm^3 and platelet count of >/= 100,000/mm^3), adequate liver function [aspartate aminotransferase (AST or SGOT) or alanine aminotransferase (ALT or SGPT) </= 2.5 times normal for patients without liver metastasis and ALT (SGPT) and AST (SGOT) </= 5, times normal for patients with liver metastasis], serum bilirubin </= 2 mg/dl), and adequate renal function (BUN and creatinine >/= 1.5 times institutional normal) prior to starting therapy
- As TPI 287 may interfere with Coumadin dosing, patients who are taking TPI 287 will require monitoring of their Prothrombin Time (PT), Partial thromboplastin time (PTT) and International Normalized Ratio (INR)
- Females of childbearing potential (non childbearing is defined as greater than one year post-menopausal or surgically sterilized) must use acceptable contraceptive methods (abstinence, intrauterine device, oral contraceptive or double barrier device), and must have a negative serum or urine pregnancy test within 7 days prior to beginning treatment on this trial. Sexually active men must also use acceptable contraceptive methods for the duration of time on study.
- Patient should be 15 years of age or older
Who cannot join
- 1. Patients with brain metastases not stable for 2 months.
- Patients taking primidone, carbamazepine, phenobarbital or phenytoin anticonvulsants (Enzyme-Inducing Anti-Epileptic Drugs - EIAED). Patients changing from these anticonvulsants to others that are allowed must be off the drugs listed above for at least 1 week before start of treatment.
- Patients with > Grade 2 neuropathy
- Patients with uncontrolled high blood pressure (systolic BP > 140 for patients < 50 years old and >160 for patients > 50 and/or diastolic BP>90 for patients< 50 year old and >99 for patients over 50) unstable angina, symptomatic congestive heart failure, clinical history of myocardial infarction within the previous six months, or serious uncontrolled cardiac arrhythmia as determined by the principal investigator.
- Because of the concerns for the potential interaction of TPI 287 and medications taken by patients who are HIV positive or have AIDS related diseases, patients who are HIV positive are not eligible for entry into this study. Only patients with suspected HIV will be tested and if positive, will be ineligible.
- Patients with a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix) are ineligible unless in complete remission and off of all therapy for that disease for a minimum of 3 years.
Show all 9Show fewer
- Patients with: a. Active infection associated with fever lasting more than 24 hours requiring antibiotics b. Disease that will obscure toxicity or dangerously alter drug metabolism c. Serious intercurrent medical illness The Principal investigator or his designee will make the final decision regarding eligibility for enrollment.
- Female patients who are pregnant or breastfeeding
- Patients younger than 15 years of age
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Phase I/II Open-Label Study of TPI 287 for Patients With Metastatic Melanoma
The goal of this clinical research study is to find the highest tolerable dose of TPI 287 that can be given to patients with metastatic melanoma. Researchers want to find out if TPI 287 can control the disease. The safety of TPI 287 will also be studied.
Read the detailed description
The Study Drug TPI 287 is designed to block tumors from growing by preventing cancer cells from dividing, which may cause them to die.
Study Groups:
Patient will be assigned to a study group based on when they join this study. Up to 4 groups of 3-6 participants will be enrolled in the Phase I portion of the study, and up to 64 participants will be enrolled in Phase II.
If patient is enrolled in the Phase I portion, the dose of TPI 287 they receive will depend on when they joined this study. The first group of participants will receive the lowest dose level of TPI 287. Each new group will receive a higher starting dose of TPI 287 than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of TPI 287 is found.
If patient is enrolled on one of the earlier dose levels, and they do not experience intolerable side effects after 2 study cycles, their dose may be increased to the next higher dose level that has been shown to be safe.
If patient has intolerable side effects, their dose may be lowered, paused, or stopped completely. This will be up to their doctor.
If patient is enrolled in the Phase II portion, they will receive TPI 287 at the highest dose that was tolerated in the Phase I portion.
Study Drug Administration:
Each study cycle is about 28 days (+/- 3 days).
TPI 287 will be given by vein over about 1 hour, on Days 1, 8, and 15 (+/- 2 days) of each study cycle.
Since TPI 287 does not mix well in water, patient will receive doses of TPI 287 that have been dissolved in cremophor. Cremophor is a chemical that is created from castor oil. Some participants may be allergic to cremophor. Before patient receives each dose of TPI 287, they will receive dexamethasone, Benadryl (diphenhydramine), and Pepcid (famotidine) by vein, to help prevent allergic reaction. Each of these medications will be given over about 10 minutes. Patient will also receive drugs to prevent nausea and vomiting. The study staff will tell patient more about these drugs and the risks for them.
Study Visits:
At all study visits, patient will be asked about any symptoms they may be having and any drugs they may be taking.
On Days 1, 8, 15, and 21 of each cycle, blood (about 1 teaspoon) will be drawn for routine tests. The blood sample on Day 21 may be drawn at a clinic near patient's home. The study staff will give patient more information about this.
On Day 28 of each cycle:
- Patient will have a physical exam, including measurement of their height, weight, and vital signs.
- Patient's performance status will be recorded.
- Blood (about 1 teaspoon) will be drawn for routine tests.
- If the doctor thinks it is needed, patient will have an MRI scan of the brain to check the status of the disease.
- If the doctor thinks it is needed, patient will have a neurological exam.
On Day 1 of Cycle 2 and then every other cycle after that (Cycles 2, 4, 6, and so on), patient will have a CT scan of their chest, abdomen, and pelvis to check the status of the disease.
Every 8 weeks, patient will have a CT or MRI scan of the brain to check the status of the disease. If patient has brain metastasis, they will have a CT or MRI scan every 4 weeks.
Length of Study:
Patient may continue taking the study drug for up to 6 months. Treatment beyond 6 months will be decided by patient's doctor. Patient will be allowed to continue taking the study drug for as long as the doctor thinks it is in their best interest. Patient will no longer be able to take the study drug if the disease gets worse, if intolerable side effects occur, or if they are unable to follow study directions.
Patient's participation on the study will be over once they have completed the end-of-treatment visit and follow-up.
End-of-Treatment Visit:
About 4 weeks after patient stops receiving TPI 287, they will have an end-of-treatment visit. At this visit, the following tests and procedures will be performed:
- Patient will have a physical exam, including measurement of their weight and vital signs.
- Patient's performance status will be recorded.
- Patient will be asked about any problems or side effects they may be having.
- Blood (about 2 tablespoons) will be drawn for routine tests.
- If patient's doctor thinks it is needed, they will have a CT or MRI scan to check the status of the disease.
Follow-Up:
- Patient will be contacted by phone or they will come in for a clinic visit. The phone call should last about 5 minutes. Patient will be asked about any problems or side effects they may be having:
- Every 2 months unless the disease gets worse.
- Then, every 3 months after that.
These follow-ups end 3 years after they enrolled in the study.
This is an investigational study. TPI 287 is not FDA approved or commercially available. It is currently being used for research purposes only.
Up to 82 patients will take part in this study. All will be enrolled at M. D. Anderson.
- Conditions
- Metastatic Melanoma
- Being tested
- TPI 287
- Keywords
- melanoma, TPI 287, tumor recurrence, tumor progression, novel taxane analog
- Medical subject headings
- Melanoma, Recurrence, Disease Progression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TPI 287Drug
Starting dose of 125 mg/m2 IV via a central venous catheter (CVC) or a peripherally inserted central catheter (PICC) line over 60 minutes (+/- 10 minutes) on Days 1, 8, and 15 (+/- 2 days) of each 28 day (+/- 3 days) study cycle. The 4-week schedule composes one cycle.
| Study group | Role | What they receive |
|---|---|---|
| TPI 287 | Experimental | Starting dose TPI 287 of 125 mg/m2 intravenous (IV) for 3 weeks of 4 week schedule. Receives: Drug: TPI 287 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Maximum Tolerated Dose (MTD) TPI 287 administered weekly for three weeks out of every four in patients with metastatic melanoma
Optimal dose (MTD) of TPI 287 for the Phase II part of the study defined as level at which no dose limiting toxicities (DLTs) are experienced (3+3 dose escalation algorithm). DLT is defined as Grade 3 or higher toxicity that is reasonably likely to be associated with study treatment at 12 weeks.
Measured: With each 28 day cycle and DLTs at 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Apr 2011 (estimated)
- Study startSep 2013
- Primary completionSep 2016 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Metastatic MelanomaStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- Cortice Biosciences, Inc.
- Responsible party
- Sponsor
- Investigators
- Agop Y. Bedikian, MD, BS, Study chair, UT MD Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01340729
- Sponsor's protocol ID
- 2010-0839
- Status last verified
- Apr 2013
- First submitted
- 20 Apr 2011
- Last updated
- 5 Apr 2013
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Apr 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I/II Open-Label Study of TPI 287 for Patients With Metastatic Melanoma
- ClinicalTrials.gov ID
- NCT01340729
- Acronym / sponsor ID
- 2010-0839
- Conditions
- Metastatic Melanoma
- Keywords
- melanoma, TPI 287, tumor recurrence, tumor progression, novel taxane analog
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Withdrawn
- Enrolment
- 0 participants (actual)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Collaborators
- Cortice Biosciences, Inc.
- Study start
- Sep 2013
- Primary completion
- Sep 2016 (estimated)
- First posted
- 25 Apr 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical research study is to find the highest tolerable dose of TPI 287 that can be given to patients with metastatic melanoma. Researchers want to find out if TPI 287 can control the disease. The safety of TPI 287 will also be studied.
Detailed description
The Study Drug TPI 287 is designed to block tumors from growing by preventing cancer cells from dividing, which may cause them to die.
Study Groups:
Patient will be assigned to a study group based on when they join this study. Up to 4 groups of 3-6 participants will be enrolled in the Phase I portion of the study, and up to 64 participants will be enrolled in Phase II.
If patient is enrolled in the Phase I portion, the dose of TPI 287 they receive will depend on when they joined this study. The first group of participants will receive the lowest dose level of TPI 287. Each new group will receive a higher starting dose of TPI 287 than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of TPI 287 is found.
If patient is enrolled on one of the earlier dose levels, and they do not experience intolerable side effects after 2 study cycles, their dose may be increased to the next higher dose level that has been shown to be safe.
If patient has intolerable side effects, their dose may be lowered, paused, or stopped completely. This will be up to their doctor.
If patient is enrolled in the Phase II portion, they will receive TPI 287 at the highest dose that was tolerated in the Phase I portion.
Study Drug Administration:
Each study cycle is about 28 days (+/- 3 days).
TPI 287 will be given by vein over about 1 hour, on Days 1, 8, and 15 (+/- 2 days) of each study cycle.
Since TPI 287 does not mix well in water, patient will receive doses of TPI 287 that have been dissolved in cremophor. Cremophor is a chemical that is created from castor oil. Some participants may be allergic to cremophor. Before patient receives each dose of TPI 287, they will receive dexamethasone, Benadryl (diphenhydramine), and Pepcid (famotidine) by vein, to help prevent allergic reaction. Each of these medications will be given over about 10 minutes. Patient will also receive drugs to prevent nausea and vomiting. The study staff will tell patient more about these drugs and the risks for them.
Study Visits:
At all study visits, patient will be asked about any symptoms they may be having and any drugs they may be taking.
On Days 1, 8, 15, and 21 of each cycle, blood (about 1 teaspoon) will be drawn for routine tests. The blood sample on Day 21 may be drawn at a clinic near patient's home. The study staff will give patient more information about this.
On Day 28 of each cycle:
- Patient will have a physical exam, including measurement of their height, weight, and vital signs.
- Patient's performance status will be recorded.
- Blood (about 1 teaspoon) will be drawn for routine tests.
- If the doctor thinks it is needed, patient will have an MRI scan of the brain to check the status of the disease.
- If the doctor thinks it is needed, patient will have a neurological exam.
On Day 1 of Cycle 2 and then every other cycle after that (Cycles 2, 4, 6, and so on), patient will have a CT scan of their chest, abdomen, and pelvis to check the status of the disease.
Every 8 weeks, patient will have a CT or MRI scan of the brain to check the status of the disease. If patient has brain metastasis, they will have a CT or MRI scan every 4 weeks.
Length of Study:
Patient may continue taking the study drug for up to 6 months. Treatment beyond 6 months will be decided by patient's doctor. Patient will be allowed to continue taking the study drug for as long as the doctor thinks it is in their best interest. Patient will no longer be able to take the study drug if the disease gets worse, if intolerable side effects occur, or if they are unable to follow study directions.
Patient's participation on the study will be over once they have completed the end-of-treatment visit and follow-up.
End-of-Treatment Visit:
About 4 weeks after patient stops receiving TPI 287, they will have an end-of-treatment visit. At this visit, the following tests and procedures will be performed:
- Patient will have a physical exam, including measurement of their weight and vital signs.
- Patient's performance status will be recorded.
- Patient will be asked about any problems or side effects they may be having.
- Blood (about 2 tablespoons) will be drawn for routine tests.
- If patient's doctor thinks it is needed, they will have a CT or MRI scan to check the status of the disease.
Follow-Up:
- Patient will be contacted by phone or they will come in for a clinic visit. The phone call should last about 5 minutes. Patient will be asked about any problems or side effects they may be having:
- Every 2 months unless the disease gets worse.
- Then, every 3 months after that.
These follow-ups end 3 years after they enrolled in the study.
This is an investigational study. TPI 287 is not FDA approved or commercially available. It is currently being used for research purposes only.
Up to 82 patients will take part in this study. All will be enrolled at M. D. Anderson.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| TPI 287 | Experimental | Drug: TPI 287Starting dose TPI 287 of 125 mg/m2 intravenous (IV) for 3 weeks of 4 week schedule. |
Who may qualify
- Ages
- 15 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (11 listed)
- Patients with histologically proven melanoma with metastasis that is unresectable Stage III or Stage IV. This will include bulky stage III and M1-3.
- Patients must have shown unequivocal evidence for tumor recurrence or progression and should have at least one indicator lesion that can be measured in one dimension as >/= 20mm with conventional techniques (CT, MRI, and X-ray) or >/= 10mm with spiral CT scan.
- Patients with melanoma with documented metastases to the brain are eligible: a. Must be asymptomatic with stable disease for at least 2 months as determined by CT or MRI of the brain at the time of evaluation no measurable changes. b. May have had prior therapy for brain metastasis such as whole brain irradiation, stereotactic gamma ray therapy or resection of brain metastases.
- Patients may have had up to two prior cytotoxic chemotherapy regimens for their systemic disease (immunological or targeted therapy e.g. vaccine, IL-2, B-RAF inhibitors, will not be considered prior cytotoxic chemotherapy)
- All patients must sign an informed consent indicating that they are aware of the investigational nature of this study in keeping with the policies of this hospital.
Key exclusion criteria (9 listed)
- 1. Patients with brain metastases not stable for 2 months.
- Patients taking primidone, carbamazepine, phenobarbital or phenytoin anticonvulsants (Enzyme-Inducing Anti-Epileptic Drugs - EIAED). Patients changing from these anticonvulsants to others that are allowed must be off the drugs listed above for at least 1 week before start of treatment.
- Patients with > Grade 2 neuropathy
- Patients with uncontrolled high blood pressure (systolic BP > 140 for patients < 50 years old and >160 for patients > 50 and/or diastolic BP>90 for patients< 50 year old and >99 for patients over 50) unstable angina, symptomatic congestive heart failure, clinical history of myocardial infarction within the previous six months, or serious uncontrolled cardiac arrhythmia as determined by the principal investigator.
- Because of the concerns for the potential interaction of TPI 287 and medications taken by patients who are HIV positive or have AIDS related diseases, patients who are HIV positive are not eligible for entry into this study. Only patients with suspected HIV will be tested and if positive, will be ineligible.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TPI 287Starting dose of 125 mg/m2 IV via a central venous catheter (CVC) or a peripherally inserted central catheter (PICC) line over 60 minutes (+/- 10 minutes) on Days 1, 8, and 15 (+/- 2 days) of each 28 day (+/- 3 days) study cycle. The 4-week schedule composes one cycle. | Drug | TPI 287 |
Primary outcome
Maximum Tolerated Dose (MTD) TPI 287 administered weekly for three weeks out of every four in patients with metastatic melanoma
Time frame: With each 28 day cycle and DLTs at 12 weeks
Optimal dose (MTD) of TPI 287 for the Phase II part of the study defined as level at which no dose limiting toxicities (DLTs) are experienced (3+3 dose escalation algorithm). DLT is defined as Grade 3 or higher toxicity that is reasonably likely to be associated with study treatment at 12 weeks.
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Apr 2013.
- UT MD Anderson Cancer Center websiteLink provided by the sponsor.
Related trials for Metastatic Melanoma
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 1
IL-17 Blockade to Decrease irAEs (REPLAY)
Metastatic Melanoma
RecruitingPhase 3
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Melanoma
RecruitingPhase 1
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Melanoma
Active, not recruitingPhase 1/2
A Study of ST-1898 for Unresectable or Metastatic Melanoma
Unresectable or Metastatic Melanoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Agop Y. Bedikian, MD, BS study chair
UT MD Anderson Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing TPI 287 in people with Metastatic Melanoma, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 5 Apr 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Maximum Tolerated Dose (MTD) TPI 287 administered weekly for three weeks out of every four in patients with metastatic melanoma (time frame: With each 28 day cycle and DLTs at 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Apr 2013.